ArticleFrontiers in physiology2022

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.

Samantha K Sarkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.